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Background: Genetic variants of NOD2 are linked to inflammatory bowel disease (IBD) etiology.
Results: DSS model of colitis in wild-type and inducible nitric-oxide synthase (iNOS) null mice revealed that NOD2-iNOS/
NO-responsive microRNA-146a targets NUMB gene facilitating Sonic hedgehog (SHH) signaling.
Conclusion:miR-146a-mediated NOD2-SHH signaling regulates gut inflammation.
Significance: Identification of novel regulators of IBD provides new insights into pathophysiology and development of new
therapy concepts.
Inflammatory bowel disease (IBD) is a debilitating chronic
inflammatory disorder of the intestine. The interactions between
enteric bacteria and genetic susceptibilities aremajor contributors
of IBD etiology. Although genetic variants with loss or gain of
NOD2 functions have been linked to IBD susceptibility, the
mechanisms coordinating NOD2 downstream signaling, espe-
cially in macrophages, during IBD pathogenesis are not pre-
cisely identified. Here, studies utilizing the murine dextran
sodium sulfate model of colitis revealed the crucial roles for
inducible nitric-oxide synthase (iNOS) in regulating pathophys-
iology of IBDs. Importantly, stimulation of NOD2 failed to acti-
vate Sonic hedgehog (SHH) signaling in iNOS null macro-
phages, implicatingNOmediated cross-talk betweenNOD2and
SHH signaling. NOD2 signaling up-regulated the expression of
a NO-responsive microRNA, miR-146a, that targeted NUMB
gene and alleviated the suppression of SHH signaling. In vivo
and ex vivo studies confirmed the important roles for miR-146a
in amplifying inflammatory responses. Collectively, we have
identified new roles for miR-146a that established novel cross-
talk between NOD2-SHH signaling during gut inflammation.
Potential implications of these observations in therapeutics
could increase the possibility of defining and developing better
regimes to treat IBD pathophysiology.
The nucleotide-binding oligomerization domain (NOD)5
leucine-rich repeat containing receptor (NLR) protein family
orchestrates intracellular surveillance tomediate innate immune
responses and inflammation (1, 2). Among the several NOD leu-
cine-rich repeat-containing receptor proteins, NOD2 acts as an
important innate sensor that detects cytosolic pathogen-associ-
ated molecular patterns as well as damage-associated molecular
patterns.Muramyldipeptide (MDP), a componentof bacterial cell
wall, is recognized by NOD2 to effectuate immune responses
including the production of important cytokines such as IL-1,
IL-6,TNF-, and IL-10 viaNF-B (3). Interestingly,NOD2plays a
crucial role during several human disorders. Polymorphisms in
NOD2 gene are shown to be associated with an assortment of
inflammatory conditions such as IBDs (4, 5). Thus, the functional
attributes of NOD variants gain immense importance as critical
regulators of inflammation.
IBDs are a group of chronic and relapsing inflammatory con-
ditions of the intestinal lining that are characterized by abdom-
inal pain, diarrhea, and severe rectal bleeding. IBDs are broadly
categorized into two subtypes among which Crohn disease
(CD) represents themost severe formof the pathogenesis (6, 7).
Notably, NOD2 is one of the first genes to be linked to IBD
susceptibility, and more than 60 NOD2 genetic variants are
reported to be associated with CD (8). NOD2 variants confer
defective sensing of the agonist, MDP, andNF-B activation by
either not executing the role to restrain inflammation (loss of
function) or directly activating expression of several proin-
flammatory genes (gain of function) (9). Consistent with
these observations, monocytes obtained from CD patients
(3020insC NOD2 frameshift mutant) show decreased ability
to produce inflammatory cytokines such as IL-1, IL-6,
TNF-, and IL-10, suggesting that 3020insC CD-associated
mutation results in loss of function. However, other studies
have reported that gain of function variant-associated CD
macrophages or epithelial cells show elevatedNF-B activation
and production of IL-1, IL-6, and TNF- (10). Further,
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patients with CD respond paradoxically to anti-TNF- treat-
ments, presenting an interesting conundrumabout the involve-
ment of NOD2 variants in the pathogenesis of CD (9). Despite
the wealth of information available regarding the identities of
NOD2 variants, the precise role and dynamics of NOD2 signal-
ing and its contribution in initiating and controlling inflamma-
tion remain unclear.
Intriguingly, the pathology of IBDs is a result of the complex
association between genetic and environmental factors that
lead to exaggerated inflammatory immune responses and the
destruction of intestinal mucosa (7). The knowledge of cellular
programming in initiation, development, and manifestation of
IBDs is insufficiently understood. However, several evidences
implicate a vital role for deregulated host responses to gut
microbiota during IBDs. This evidence includes excessive
superoxides andNO produced by immune cells such asmacro-
phages that culminate in defective intestinal mucosal barrier
functions (11). Although NO is an important secondary mes-
senger thatmodulates normal cellular functions and gut home-
ostasis, the sustained production of NO results in detrimental
effects (12). Further, inducible nitric-oxide synthase (iNOS)-
induced NO has been implicated to play a vital role in arbitrat-
ing the inflammatory response during colitis (13).Nevertheless,
the studies on the molecular mechanism involved in NO-me-
diated immune homeostasis during IBD are scanty. In this
regard, recent investigations have underscored the ability of
NO to regulate key signaling networks including Sonic hedge-
hog (SHH) pathways (14). Remarkably, SHH signaling is asso-
ciated with processes such as gut development and mainte-
nance of gut homeostasis (15, 16). Additionally, inflammatory
environments often trigger increased expression of SHH
ligands (17, 18). In this perspective, the current study attempts
to delineate the role for SHH signaling during the onset or
establishment and the perpetuation of IBDs.
Here, we identified a novel cross-talk between NOD2 and
SHH signaling pathways in macrophages. Notably, our data
delineate a prominent role of miR-146a/SHH signaling in
amplifying inflammatory responses and provide a mechanistic
understanding of gain-of-function variants of NOD2 in the
pathogenesis of human IBDs.
EXPERIMENTAL PROCEDURES
Cells and Mice—Primary macrophages were isolated from
peritoneal exudates of C57BL/6 wild-type (WT) and iNOS/
mice. Brewer thioglycollate (8%) was used to enrich macro-
phages in the peritoneal cavity of mice. The cells were cultured
in DMEM (Life Technologies) containing 10% FBS (Sigma-Al-
drich) for 6–8 h, and adherent cells were used as peritoneal
macrophages. The purity of these macrophages was confirmed
by F4/80 staining using FACS and was found to be 95%. All
transfection studies were carried out with murine RAW 264.7
macrophage-like cells. All studies involving mice were carried
out after the approval from the Indian Institute of Science,
Institutional Ethics Committee for Animal Experimentation as
well as from the Institutional Biosafety Committee.
Reagents and Antibodies—General laboratory chemicals
were obtained from Sigma-Aldrich or Merck (Darmstadt,
Germany). MDP, anti-iNOS, and anti--actin antibodies
were purchased from Sigma-Aldrich. Anti-SHH, anti-GLI1,
anti-PTCH1, anti-NUMB, anti-Ser-9 phospho-GSK-3, and
anti-p65 antibodies were purchased from Cell Signaling
Technology (Danvers, MA). Anti-proliferating cell nuclear
antigen antibody was purchased from Calbiochem. HRP-con-
jugated anti-rabbit IgG and HRP-conjugated anti-mouse IgG2a
were obtained from Jackson ImmunoResearch Laboratories
(West Grove, PA).
Treatment with Pharmacological Reagents—The pharmaco-
logical reagents were purchased fromCalbiochem. In all exper-
iments,macrophageswere treatedwith inhibitors for 1 h before
experimental treatments at the following concentrations: SIN1
(20 M), 1400W (100 M), PP2 (10 M), BAY 11-7082 (20 M),
betulinic acid (10M), and cyclopamine (10M).Dimethyl sulf-
oxide (DMSO) at 0.1% concentration was used as the vehicle
control. In all experiments involving pharmacological reagents,
a tested concentration of respective inhibitor was used after
careful titration experiments assessing the viability of the
macrophages using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay.
RNA Isolation and Quantitative Real Time RT-PCR—
Macrophages were treated as indicated, and total RNAwas iso-
lated using TRI reagent (Sigma-Aldrich). 2g of total RNAwas
converted into cDNA using first-strand cDNA synthesis kit
(Bioline, London, UK). Quantitative real time RT-PCRwas per-
formed using SYBRGreen PCRmixture (Kapa Biosystems Inc.,
Woburn, MA) for quantification of the target gene expression.
All the experiments were repeated at least three times inde-
pendently to ensure the reproducibility of the results. The
primers used in the study areGapdh forward 5-gagccaaacgggt-
catcatct-3,Gapdh reverse 5-gaggggccatccacagtctt-3; Shh for-
ward 5-aaagctgacccctttagccta-3, Shh reverse 5-ttcggagtttctt-
gtgatcttcc-3; Gli1 forward 5-ccaagccaactttatgtcaggg-3, Gli1
reverse 5-agcccgcttctttgttaatttga-3; Gli2 forward 5-caacgcc-
tactctcccagac-3, Gli2 reverse 5-gagccttgatgtactgtaccac-3;
Smo forward 5-gagcgtagcttccgggacta-3, Smo reverse 5-ctgg-
gccgattcttgatctca-3; Ptch1 forward 5-gccacagcccctaacaaaaat-
3, Ptch1 reverse 5-acccacaatcaactcctcctg-3; Il-12 forward 5-
gacttgaagatgtaccagacag-3, Il-12 reverse 5-gagatgagatgtgatgg-
gag-3; Tnf- forward 5-agcccacgtcgtagcaaaccaccaa-3, Tnf-
reverse 5-acacccattcccttcacagagcaat-3; Ccl5 forward 5-ttcc-
ctgtcatcgcttgctct-3, Ccl5 reverse 5-cggatggagatgccgatttt-3;
Cxcl9 forward 5-tcttttcctcttgggcatcatctt-3, Cxcl9 reverse 5-
tttccccctcttttgctttttctt-3; and Il-6 forward 5-cttcttgggactgatg-
ctggtg-3, Il-6 reverse 5-caggatttcccagagaacatgtg-3.
Quantification of miRNA Expression—For detection of miR-
146a by quantitative real time RT-PCR, total RNA was isolated
from treated or untreated macrophages. Quantitative real time
RT-PCR for miR-146a was done using TaqMan miRNA assays
(Applied Biosystems-Invitrogen) as per the manufacturer’s
instructions. U6 snRNA was used for normalization.
Immunoblotting—Macrophages were lysed in radioimmu-
noprecipitation assay buffer consisting of 50 mM Tris-HCl (pH
7.4), 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, 1 g/ml each of aprotinin,
leupeptin, and pepstatin, 1 mM Na3VO4, and 1 mM NaF. An
equal amount of protein from each cell lysate was resolved in a
12% SDS-polyacrylamide gel and transferred to polyvinylidene
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difluoridemembranes (Millipore, Billerica,MA) by the semidry
transfer (Bio-Rad) method. The blots were blocked with 5%
nonfat drymilk powder in TBST (20mMTris-HCl (pH 7.4), 137
mM NaCl, and 0.1% Tween 20) for 60 min to remove nonspe-
cific binding. The blots were incubated overnight at 4 °C with
primary antibody followed by incubation with goat anti-rabbit-
HRP or anti-mouse-HRP secondary antibody in 5%BSA for 2 h.
The immunoblots were developed with enhanced chemilumi-
nescence detection system (PerkinElmer Life Sciences) as per
the manufacturer’s instructions. All immunoblots are repre-
sentatives of at least three independent experiments.
Nuclear and Cytosolic Subcellular Fractionation—Macro-
phages were harvested and gently resuspended in Buffer A
(10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, and 0.5 mM PMSF). After incubation on
ice for 15 min, cell membranes were disrupted with 10%
Nonidet P-40. The cytosolic extract was separated by cen-
trifugation at 13,000 rpm for 15 min at 4 °C. The pellet was
lysed with Buffer C (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF), and the
nuclear protein extract was collected. The nuclear and cyto-
solic fractions were resolved on denaturing polyacrylamide
gel, and further processing was done as mentioned as
described under “Immunoblotting.”
In Vivo Studies In Mice Using Murine DSS Model of Colitis—
Themurine colitis model of intestinal inflammation was estab-
lished using low molecular weight dextran sodium sulfate
(DSS) as described below.WT and iNOS/mice were divided
into two groups containing six mice each. The test group was
administered drinking water supplementedwith lowmolecular
weight DSS solution (2.5%), whereas the control group of mice
was fed with autoclaved water for 9 days. Mice were carefully
monitored every day for clinical symptoms such as weight loss,
bloody stools, and diarrhea. After 7, 8, or 9 days of DSS treat-
ment, the clinical symptoms of IBD were scored in WT and
their iNOS/ littermates. The clinical scores were given as
FIGURE1.NOD2pathwayactivatesSHHsignaling.AandB,mouseperitonealmacrophageswere stimulatedwithMDPat the indicatedconcentrations.Aand
B show transcript and protein level changes in the SHH activation markers and nuclear translocation of GLI1. Med, medium; PCNA, proliferating cell nuclear
antigen. C and D, time kinetics analysis of SHH signaling activation at both transcript (C) and protein levels (D) upon stimulation of NOD2 pathway is shown.
E and F, macrophageswere treatedwith PP2, a RIP2 kinase inhibitor, prior toMDP treatment and status of SHH signaling induction, and activationwas assayed
at transcript (E) or protein levels (F). G, RAW 264.7 cells were transfected with siRNAs specific to Nod2, Rip2, and Tak1, and activation of SHH signaling was
assayed by immunoblotting. NT, nontargeted siRNA. *, p 0.05 versus control; **, p 0.05 versusMDP treatment (one-way ANOVA).
MicroRNA-146a Regulates SHH Signaling and Inflammation
NOVEMBER 15, 2013•VOLUME 288•NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 33039
 by guest on N
ovem
ber 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
follows: 0  no symptoms; 1  diarrhea; 2  rectal bleeding;
and 4 death. At the end of DSS treatment, mice were eutha-
nized, and colons and small intestines were dissected. The total
length of colon in both groups of WT and iNOS/ mice was
measured, and colon was divided into three parts as ascending
colon, transverse colon, and descending colon. Each of these
samples was processed for total RNA isolation.
Transfection Studies—RAW 264.7 macrophage cells were
transfected with 100 nM siRNA or miRNA mimic using Oligo-
fectamine (Invitrogen) according to the manufacturer’s instruc-
tions. Transfection efficiencywas found to bemore than50% in all
the experiments as determined by counting the number of siGLO
lamin A/C-positive cells in amicroscopic field using a fluorescent
microscope. 48 h after transfection, respective experiments were
performed as indicated.Nod2, Rip2, Tak1, Shh,Gli1, and control
siRNAs were obtained from Dharmacon (Waltham, MA) as
siGENOMETM SMARTpool reagents, which contain a pool of
four different double-stranded RNA oligonucleotides. miR-146a
mimic, miR-146a inhibitor (Anti-miRTM), and control mimics
were purchased from Ambion-Invitrogen. RAW 264.7 macro-
phages were transiently transfected with the following constructs
using low molecular weight polyethylenimine (PEI) (Sigma-Al-
drich): pcDNA3 vector, pcDNA3 SHH vector, pcDNA3 NUMB
vector, pGVP2-NUMB 3-UTR luciferase reporter construct,
pGVP2-NUMB3-UTRreverse luciferase reporter construct,WT
miR-146a promoter luciferase construct, and mutant miR-146a
promoter luciferase for binding sites of transcription factors
NF-B, c-ETS, PU.1, c-Myc, HSF2, and Oct-1 constructs. 48 h
after transfection, the cells were treated as described and pro-
cessed as required.
Luciferase Assays—RAW 264.7 macrophages were trans-
fected with NUMB 3-UTR construct, NUMB 3-UTR reverse
construct, along with -galactosidase vector and indicated
miRNA mimics or treatments. After 48 h of transfection, cells
were lysed in reporter lysis buffer (Promega, Madison,WI) and
assayed for luciferase activity using luciferase assay reagent.
The results were normalized for transfection efficiencies by
assay of -galactosidase activity.
FIGURE 2. NOmediates NOD2-driven activation of SHH signaling. A, macrophages were treated with various concentrations of MDP as indicated. mRNA
levels of Inos were assayed by quantitative real time RT-PCR, and change in nitrate production was measured using Griess reagent. B, macrophages were
treatedwithMDP, and kinetics of iNOS expression and NOproductionwere assayed by immunoblotting and Griess reagent, respectively (mean S.E., n 3).
Med, medium. C andD, iNOS expression andNOproductionwere analyzed by inhibition of NOD2 signaling by PP2 (C) orNod2-, Rip2-, and Tak1-specific siRNAs
(D). *, p  0.05 versus control; **, p  0.05 versus MDP treatment or MDP-treated nontargeted (NT) siRNA (one-way ANOVA). E and F, iNOS null and WT
macrophageswere treatedwithMDPor SIN1, and the activation status of SHH signalingwasmonitored at the transcript (E) andprotein levels (F).WT, wild type;
iNOS/, iNOS knock-out.G, BAY 11-7082, an IB inhibitor, was used tomonitor activation of SHH signaling upon activation of NOD2 pathway byMDP or with
exogenous supply of NO by SIN1. *, p 0.05 versus control; **, p 0.05 versusWTMDP treatment (one-way ANOVA).
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Statistical Analysis—Levels of significance for comparison
between samples were determined by the Student’s t test distri-
bution and one-way ANOVA. The data in the graphs are
expressed as the mean S.E., and p values 0.05 were defined
as significant. GraphPad Prism 3.0 software (GraphPad soft-
ware, San Diego, CA) was used for all the statistical analyses.
RESULTS
iNOS/NO Mediates NOD2-SHH Signaling Cross-talk—NOD2
signaling is a central cytosolic surveillance pathway as well as a
crucial regulator of inflammation (2). However, NOD2-mediated
molecular regulators of inflammatory responses have not been
clearly identified and studied. In this regard, recent studies have
indicated a strong role for SHH signaling during inflammation
(19). We thus analyzed the potential role of SHH signaling as a
NOD2-responsive pathway. The SHH signaling activation is
marked by induced expression of SHH, glioma-associated
oncogene family zinc finger (GLI)1, GLI2, smoothened (SMO),
Patched 1 (PTCH1), and nuclear translocation of transcrip-
tional activator GLI1 (20). Treatment of macrophages byMDP,
a NOD2 agonist, showed robust induction as well as activation
of SHH signaling with increase in NOD2 signaling activation
(Fig. 1, A–D). To ascertain the involvement of NOD2-arbi-
trated RIP2-TAK1 signaling in controlling SHH pathway, the
expression levels of SHH signaling molecules were assayed in
the presence of the RIP2-specific inhibitor, PP2. The inactiva-
tion of RIP2 kinase activity by PP2 showed significant reduction
in MDP-triggered SHH signaling (Fig. 1, E and F). The utiliza-
tion of Nod2-, Rip2-, and Tak1-specific siRNAs validated the
involvement of NOD2 signaling in regulating the activation of
SHH signaling (Fig. 1G). Together, these observations strongly
suggest that NOD2 signaling holds the capacity to control acti-
vation of SHH signaling.
Recent studies have demonstrated that NOD2 signaling acti-
vation in macrophages increases the expression of TNF-, IL-6,
COX-2, and iNOS (21, 22). Further, NO initiates and mediates
cross-talks with other signaling pathways including NOTCH and
WNT signaling (21, 23). Thus, we hypothesized that NOD2-in-
duced iNOS expression and sustained production of NO could
be vital to arbitrate cross-talks with SHH signaling. From this
perspective, kinetics analysis of iNOS expression in MDP-
treatedmacrophages showed an induced expression of iNOS as
FIGURE3.NOD2pathwaymodulatesNUMBexpression toactivateSHHsignaling.A andB, expressionofNUMB inmacrophageswithMDP treatment at the
indicated (A) time points and (B) concentrations was assessed using immunoblotting. Med, medium. C and D, macrophages were treated with various
concentrations ofMDP (C) or at different time points (D) as indicated. The change inmRNA levels ofNumbwas assayed by quantitative real time RT-PCR. E and
F, Nod2-, Rip2-, and Tak1-specific siRNA-transfected RAW 264.7 macrophages (E) or PP2-pretreated macrophages (F) were analyzed for NUMB expression. NT,
nontargeted siRNA.G, WT or iNOS null macrophages were treatedwithMDP or SIN1, and expression of NUMB uponMDP treatment was determined.WT, wild
type; iNOS/, iNOS knock-out. H and I, pcDNA3 NUMB-transfectedmacrophages were assessed for activation of SHH signaling at transcript levels (H) as well
as at protein levels and by nuclear translocation of GLI1 (I). *, p 0.05 versus control; **, p 0.05 versus pcDNA3 MDP treatment (one-way ANOVA).
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well as NO production (Fig. 2, A and B). The loss of NOD2
signaling functions by perturbations mediated by pharmaco-
logical inhibitor of RIP2 or specific siRNAs to Nod2, Rip2, and
Tak1 confirmed NOD2 signaling-dependent iNOS expression
and NO production (Fig. 2, C and D and data not shown). This
affirms NO as a mediator of NOD2 signaling. We further eval-
uated the role of NOD2-responsive NO to activate SHH signal-
ing. Interestingly, iNOS null macrophages showed compro-
mised ability to trigger NOD2-induced activation of SHH
signaling as compared with WTmacrophages (Fig. 2, E and F).
The inadequacy of iNOS null macrophages to activate SHH
signalingwas not a result of generalized defect as the addition of
an NO donor, SIN1, showed augmented activation of SHH sig-
naling in iNOS null macrophages, which is comparable with
that of WT macrophages (Fig. 2F and data not shown).
NOD2 receptors have been known to utilize NF-B to regu-
late expression of downstream genes (24). To dissect the role of
NF-B during NOD2-iNOS/NO-mediated activation of SHH
signaling, macrophages were treated with MDP or SIN1 in the
presence or absence of a NF-B inhibitor, BAY 11-7082 (which
prevents IB- phosphorylation). As represented in Fig. 2G,
inhibition of NF-B activity showed a significant decrease in
SHH signaling activation. As a proof of concept, we monitored
NF-B translocation from cytosol to nucleus with MDP or
SIN1 treatment of macrophages (data not shown). These data
conclusively suggest NO as a potential link for NOD2-SHH
signaling cross-talk.
NOD2 Attenuates NUMB Gene Activity—The binding of
SHH ligand to PTCH1 receptors derepresses PTCH1-mediated
suppression of SMO that culminates into destabilization of
inhibitory complex and nuclear translocation of GLI1 to the
promoters of SHH-responsive genes (20). However, checks and
balances in terms of activation of SHH signaling are carefully
regulated by the NUMB-mediated negative regulatory loop.
FIGURE 4. NOD2/NO axis regulates expression of miR-146a. A, miR-146a expression was determined in macrophages stimulated with MDP using quanti-
tative real time RT-PCR. B, macrophages pretreated with RIP2 kinase inhibitor, PP2, were assayed for miR-146a expression after MDP treatment. *, p  0.05
versus control; **, p  0.05 versus MDP treatment (one-way ANOVA). Med, medium. C, iNOS null or WT macrophages were treated with MDP or SIN1, and
expression levels ofmiR-146awere analyzed as described.WT, wild type; iNOS/, iNOS knock-out.D and E, miR-146a promoter-transfected cells were treated
with the indicated concentrationsofMDP (D) orwith 1400W, iNOSactivity inhibitor, prior toMDP stimulation (E), andmiR-146apromoter luciferase activitywas
measured.Alternatively, cellswere stimulatedwithSIN1 inpanel E, andmiR-146apromoter activitywas assayed. *,p0.05 versusWTcontrol; **,p0.05 versus
WTMDP (one-way ANOVA). RLU, relative luciferase unit. F, WTmiR-146a promoter luciferase construct or mutant miR-146a promoter luciferase constructs for
binding sites of indicated transcription factors were used to assess MDP-inducedmiR-146a promoter reporter activity by luciferase assay (mean S.E., n 3).
*, p 0.05 versusWT control; **, p 0.05 versusWTMDP (one-way ANOVA).
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Recent studies have implicated NUMB in GLI1 degradation
through ITCH (Itchy E3 ubiquitin protein ligase)-dependent
ubiquitination, sequestering active forms of GLI1 transcription
factors and suppression of GLI transcriptional activity (25, 26).
In this perspective, we analyzed the NOD2-mediated regula-
tion of NUMB gene expression. The dosage dependence and
time kinetics analysis demonstrated the progressive decrease in
theNUMBprotein levels with increase inNOD2-MDP engage-
ment (Fig. 3, A and B). However, there was no significant
change observed at transcript levels of NUMB (Fig. 3,C andD).
Further, NOD2 signaling interference by Nod2-, Rip2-, or
Tak1-specific siRNAs or PP2 led to the significant alleviation of
MDP-induced decrease in NUMB levels (Fig. 3, E and F). In
agreement with the previous results, the exogenous supply of
NO by SIN1 showed a decrease in NUMB protein levels,
whereas iNOS null macrophages failed to exhibit such effects
(Fig. 3G). Gain-of-function studies were undertaken to further
validate the role of NUMB in regulating NOD2-driven SHH
signaling. The activation of SHH signaling in response to MDP
was severely compromised in the NUMB protein overexpress-
ing macrophages as compared with that of control cells (Fig. 3,
H and I) as analyzed by expression of SHH, GLI1, GLI2, SMO,
PATCH1, and nuclear translocation of transcriptional acti-
vator GLI1. Altogether, these results summarize and con-
firm that NOD2-iNOS/NO-triggered SHH signaling activa-
tion is mediated through down-regulation of NUMB protein.
NOD2-inducedmiR-146aPotentiatesSHHSignalingActivation
byTargetingNUMBGene—Thedown-regulationofNUMBupon
NOD2signalingat theprotein levels butnot at the transcript levels
implicated the possible intervention of post-transcriptional regu-
lations mediated by microRNAs. In this regard, NUMB has been
identified as a potential target of miR-146a (27). Besides, miR-
146a is one of the first identified inflammatory miRNAs whose
expression was found to be elevated during various inflamma-
tory conditions (28, 29). Further, extensive bioinformatic algo-
rithms validated that miR-146a targets an 8-mer site located at
residues spanning 2899–2906 inmouseNUMB3-UTR. In this
perspective, we analyzed the contribution of miR-146a, if any,
in modulating NOD2/NO-mediated SHH signaling. As illus-
trated in Fig. 4A, miR-146a levels increased gradually inmacro-
phages with increasing doses of MDP. NOD2 signaling
interference with PP2 showed significant reduction in MDP-
FIGURE 5.miR-146amodulates SHH signaling by targetingNUMB. A–C, pGVP2-NUMB 3-UTR luciferase reporter construct or pGVP2-NUMB 3-UTR reverse
luciferase reporter construct (3-UTR is in reverse orientation)-transfectedmacrophageswere treatedwithMDP (A) or SIN1 (B) or co-transfectedwithmiR-146a
mimics (C) to analyzeNUMB3-UTR luciferase activity (mean S.E.,n 3) (one-wayANOVA) orNUMBprotein levels.Med,medium;RLU, relative luciferase unit.
D and E, miR-146a mimic-transfected macrophages were assessed for activation of SHH signaling at protein (D) and transcript levels (E).
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induced expression of miR-146a (Fig. 4B). Further, iNOS null
macrophages showed compromised ability to inducemiR-146a
expression. Concordantly, SIN1-induced expression of miR-
146a was comparable in both iNOS null andWTmacrophages
(Fig. 4C). The miR-146a promoter luciferase reporter assays
validated the crucial role of NOD2-iNOS signaling in the
expression of miR-146a. (Fig. 4, D and E). Promoter luciferase
analysis with WT and mutant miR-146a promoters revealed
NF-B along with HSF2, PU.1, Oct1, c-ETS, and c-Myc as vital
transcription factors that orchestrate NOD2-mediated expres-
sion of miR-146a (Fig. 4F).
To ascertain the miR-146a-NUMB interactions, we uti-
lized WT NUMB 3-UTR and NUMB 3-UTR reverse (lucif-
erase construct that harbors NUMB 3-UTR in reverse direc-
tion). As represented in Fig. 5, A and B, MDP or SIN1
treatment considerably reduced WT NUMB 3-UTR lucifer-
ase activity, but not NUMB 3-UTR reverse luciferase activity.
Importantly, enforced miR-146a expression through miR-146a
mimics markedly reduced NUMB 3-UTR luciferase activity as
well asNUMBprotein levels, validatingNUMBasadirect targetof
miR-146a (Fig. 5C). The positive regulation of SHH signaling by
miR-146a was confirmed by enforced expression of miR-146a
in macrophages, which triggered activation of SHH signaling
(Fig. 5, D and E).
NOD2-iNOS/NO-miR-146a-mediated SHH Signaling Regu-
lates Inflammatory Gene Expression—As mentioned earlier,
several independent studies have suggested that NOD2 signal-
ing and SHH signaling are involved in modulating the inflam-
matory responses (2, 13, 19).Hence,we analyzed the role for the
miR-146a-SHH signaling axis in regulating the cytokine milieu
or inflammatory gene expression during NOD2 signaling. As
shown in Fig. 6A, overexpression of SHH in macrophages
resulted in the induced expression of Il-12, Tnf-, Il-6, Ccl5,
and Cxcl9. Corroborating these data, inhibition of SHH signal-
ing by pharmacological inhibitors such as cyclopamine (SMO
inhibitor) or betulinic acid (GLI inhibitor) significantly reduced
the ability ofMDP-NOD2 signaling to induce the expression of
these cytokines (Fig. 6B). Further, to establish the role of miR-
146a during NOD2-induced cytokine expression, we have
utilizedmiR-146a inhibitors (Anti-MiRs) andmimics. Accord-
FIGURE 6. miR-146a-mediated SHH signaling regulates inflammatory responses. A, pcDNA3 SHH-transfected macrophages were assessed for expression of
proinflammatorygenes, Il-12,Tnf-, Il-6,Ccl5, andCxcl9.B,macrophagespretreatedwithpharmacological inhibitorsofSHHsignaling, cyclopamine (inhibitsSMO),and
betulinic acid (inhibits GLI), were analyzed for the indicated genes after MDP stimulation. **, p 0.05 versus control; *, p 0.05 versusMDP (one-way ANOVA).Med,
medium.C, expression ofMDP-induced proinflammatory geneswas analyzed inmacrophages transfectedwithmiR-146a inhibitor and Control inhibitor. *, p 0.05
versusMDP Control inhibitor (MDPControl inh) (one-way ANOVA). D and E, miR-146a mimic-transfected macrophages were either treated with SHH signaling-
specific pharmacological inhibitor such as cyclopamine or betulinic acid (D) or co-transfected with Shh- or Gli1-specific siRNA (E). Quantitative real time RT-PCR for
analysis of inflammatory cytokines Il-12, Tnf-, Il-6, Ccl5, and Cxcl9was performed. *, p 0.05 versusmiR-146amimic (one-way ANOVA).NT, nontargeted siRNA.
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ingly, miR-146a inhibitor-transfected macrophages were
severely compromised in their ability to induce the expres-
sion of Il-12, Tnf-, Il-6, Ccl5, and Cxcl9 on MDP treatment
(Fig. 6C), whereas overexpression ofmiR-146a inmacrophages
was sufficient to induce these genes (Fig. 6D). Substantiating
this observation, utilization of SHH signaling-specific pharma-
cological inhibitors (Fig. 6D) or knockdown of SHH signaling
by Shh- orGli1-specific siRNAs (Fig. 6E) significantly repressed
the miR-146a mimic-induced expression of Il-12, Tnf-, Il-6,
Ccl5, and Cxcl9.
iNOS/NO-mediated SHH Signaling Is Necessary for IBD
Immunopathology in Vivo—To establish the in vivo signifi-
cance of NOD2-iNOS/NO-miR-146a-SHH signaling-induced
inflammatory responses, we utilized the well established DSS-
induced colitis murine model of mucosal inflammation. The
DSS model mimics human IBD with respect to its etiology,
pathogenesis, and therapeutic response (30, 31).
iNOS and its product NO are key regulators of acute and
chronic phases of inflammatory responses during IBDs (13).
The use of iNOS/NO inhibitors has been shown to be effective
in reducing inflammation during IBD (32). In agreement with
these previous studies (13, 32), we observed that DSS-adminis-
teredWTmice showed significant decrease in body weight and
survival as well as colon length with DSS treatment as com-
pared with results in iNOS null mice (data not shown). Because
IBDs are characterized by elevated proinflammatory cytokines
that play key roles in orchestrating remittance and exacerbationof
inflammatory responses, we analyzed the cytokine milieu or the
inflammatory signatures of DSS-mediated inflamed colons. As
shown in Fig. 7, A–D, WTmice exhibited elevated levels of Il-12,
Tnf-, Il-6,Ccl5, andCxcl9.On thecontrary, iNOSnullmice failed
to effectuate inflammatory responses on DSS treatment, suggest-
ing the essential requirement of iNOS/NO to mediate inflamma-
tory responses in IBDs.
Recent studies have implicated a crucial role of SHH signal-
ing in intestinal inflammation (19). As represented in Fig. 2,
E–G, SHH signaling activation is dependent on iNOS activity.
Thus, we explored the possible role for iNOS/NO in activation
of SHH signaling in the current in vivo model for IBDs. In
accordance with the above observations (Fig. 7, A–D), DSS-
administeredWTmice showed significant increase in SHH sig-
naling activation. However, iNOS null mice did not exhibit
FIGURE 7. Inflammatory responses during DSS-induced IBD immunopathology are controlled by iNOS/NO-miR-146a-SHH signaling. A–H, the expres-
sion levels of proinflammatory genes, Il-12, Tnf-, Il-6,Ccl5, and Cxcl9 (A–D) and SHH signalingmarkers expression (E–H) weremeasured along ascending colon
(AC), transverse colon (TC), descending colon (DC), and small intestine (SI) inWT and iNOS/ animals (n 6 each) usingquantitative real timeRT-PCR. *,p
0.05 versusDSS-treatedWTmice (Student’s t test). I–L, quantitative real time RT-PCR analysis of miR-146a after DSS treatment of WT or iNOS null animals (n
6) in ascending colon, transverse colon, descending colon, and small intestine is shown. *, p 0.05 versus WT control; **, p 0.05 versus WT DSS (one-way
ANOVA). WT, wild type; iNOS/, iNOS knock-out.
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SHH activation even with DSS administration (Fig. 7, E–H).
Corroborating these results, DSS-administered iNOS null mice
failed to induce miR-146a expression with DSS administration
along the ascending colon, transverse colon, descending colon,
and small intestine as comparedwith results inWTmice (Fig. 7,
I–L). Together, our observations suggest that iNOS/NO-miR-
146a-mediated SHH signaling activation presents a newmech-
anism for modulations of inflammatory diseases such as IBD.
DISCUSSION
NOD2 is a cytoplasmic surveillance sensor that governs
homeostasis through regulation of immune responses, inflam-
mation, and apoptosis (33–35). Several studies implicateNOD2
polymorphism in CD, the major form of IBDs. Strikingly, these
variants of NOD2 have been documented not only in CD
patients but also in healthy individuals, underscoring the pres-
ence of predisposition for development of CD (36). Although
surplus NOD2 signaling during certain kinds of CD is evi-
denced, the role of the NOD2 downstream signaling network
under such conditions is imprecisely understood. The
deeper insight into the NOD2-activated molecular signaling
is crucial for understanding NOD2-driven inflammation and
designing target-specific pharmacological agents to treat
inflammation. In this perspective, our current investigation
identifies NO-triggered miR-146a as a novel downstream
messenger of NOD2 signaling in modulating SHH signaling
and inflammatory responses.
NO often acts as a key signalingmolecule that defines critical
rate-limiting steps for pathogenesis of chronic or acute inflam-
mation across varying cellular contexts (37). Significantly,
excessive production of NO in response to a variety of patho-
logic or homeostatic stimuli leads to modulation of several cel-
lular processes (38–40). Although NO is implicated in IBD
responses, its role in inflammatory modulation remains inade-
quately understood. On the other hand, SHH signaling is a fun-
damental pathway that directs gut development and maintains
gut homeostasis through epithelial signaling (16). Studies have
also implicated elevated SHH signaling during inflammatory
diseases (19, 41). In accordance with these observations, we
explored the possible link between NO and SHH signaling.
NOD2-responsive NO was found to induce SHH signaling in
macrophages. Importantly, the in vivo DSS model revealed a
possible NOD2 gain-of-function scenario of IBD as excessive
NO-dependent SHH responses were observed in mice.
Unrestrained SHH signaling during inflammatory disorders
recurrently entails the high risk of neoplastic transformations
(42). In this context, the system of checks and balances that
diligently titers the SHH signaling by several negative regula-
tors such as NUMB assumes central importance. Corroborat-
ing our previous results, we found diminished levels of NUMB
protein due to post-transcriptional regulation by miR-146a,
which in itself is a consequence of NOD2/NO signaling. Sup-
porting this, characterized inflammatorymiRNAs such asmiR-
146a are implicated in various inflammatory diseases such as
IBD, systemic lupus erythematosus, Sjögren syndrome, and
rheumatoid arthritis (43). Furthermore, miR-146a expression
correlates with iNOS expression as documented in one study
(29). Interestingly, NO is known to mediate regulatory effects
bymodulating the activity of severalmiRNAs, suggesting a crit-
ical contribution of reactive nitrogen intermediates in modu-
lating post-transcriptional modifications (44, 45).
FIGURE 8.Molecular mechanism of DSS-induced colitis in murinemodel. NOD2-triggered iNOS/NO regulates miR-146a expression through transcription
factors, NF-B, PU.1, HSF2, and Oct-1. miR-146a thus produced targets NumbmRNA, leading to reduced expression of NUMB and activation of SHH signaling.
Overall, NOD2/NO pathway establishes cross-talk with SHH pathway via miR-146a-mediated degradation of NUMB to control inflammatory responses.
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In summary, our work demonstrates that NOD2-driven
inflammation is critically regulated by NO-responsive miR-
146a that facilitates activation of SHH signaling by targeting
NUMB expression. These molecular events contribute to the
expression of inflammatory genes such as IL-12, TNF-, IL-6,
CCL-5, and CXCL-9 (Fig. 8). The in vivo DSS-induced colitis
murine model presented unique roles for NO-dependent miR-
146a and SHH signaling during IBD especially similar to that
exemplified by the NOD2 gain-of-function variant. We believe
that various novelmolecular regulators identified in the current
study would thus serve as potential therapeutic targets.
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